Invetech and AiCella Collaborate to Enhance Cell Therapy with AI

Jul 1, 2025
Invetech and AiCella have announced a strategic collaboration to integrate AI into cell therapy production, aiming to optimize processes and improve patient outcomes.

Invetech and AiCella have announced a strategic collaboration to advance cell therapy innovation, as stated in a press release. This partnership aims to integrate AiCella's AI platform with Invetech's automation technology to enhance the development and manufacturing of cell therapies.

The collaboration focuses on embedding AiCella's predictive AI models into the cell therapy production process. This integration is expected to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and accelerate the path to scalable, patient-ready therapies.

Both companies plan to showcase their joint capabilities at upcoming industry events, including the Meeting on the Mesa in October 2025.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.